Naslov
Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019

Autori
Adámková, V ; Mareković, Ivana ; Szabó, J ; Pojnar, L ; Billová, S ; Horvat Herceg, Sanda ; Kuraieva, A ; Możejko-Pastewka, B

Izvornik
European journal of clinical microbiology & infectious diseases (0934-9723) 41 (2022), 6; 989-996

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
ATLAS ; Antimicrobial surveillance ; Ceftazidime-avibactam ; Difficult-to-treat ; Enterobacterales ; Pseudomonas aeruginosa

Sažetak
Antimicrobial susceptibility of clinical isolates collected from sites in central Europe in 2019 was tested by CLSI broth microdilution method and EUCAST breakpoints. Most active were amikacin, ceftazidime- avibactam and colistin ; respectively, susceptibility rates among P. aeruginosa (n = 701) were 89.2%, 92.2% and 99.9% ; difficult-to-treat (DTR) isolates, 62.5%, 37.5% and 100% ; multidrug- resistant (MDR) isolates, 68.3%, 72.9% and 99.5% ; meropenem-resistant (MEM- R), metallo-β-lactamase- negative (MBL-negative) isolates, 72.8%, 78.6% and 100%. Among Enterobacterales (n = 1639), susceptibility to ceftazidime-avibactam, colistin and tigecycline was ≥ 97.9% ; MDR Enterobacterales, 96.8%, 94.4% and 100%, respectively ; DTR isolates, ≥ 76.2% to ceftazidime- avibactam and colistin ; MEM-R, MBL- negative isolates, ≥ 90.0% to ceftazidime- avibactam and colistin.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA